MedDataX Logo

Bevacizumab for Central Retinal Vein Occlusion Study

NCT ID: NCT00906685

Last Updated: 2011-11-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-05-31

Study Completion Date

2011-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Central retinal vein occlusion is a leading cause of severe visual impairment. Until now, no treatment has been available to improve visual acuity. The present study intends to investigate if intravitreal bevacizumab can improve visual acuity as compared to sham-treated control patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Central Retinal Vein Occlusion

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

CRVO anti-VEGF Macular edema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intravitreal bevacizumab

Group Type ACTIVE_COMPARATOR

bevacizumab

Intervention Type DRUG

Intravitreal injection of 1.25 mg bevacizumab

Sham injection

Group Type SHAM_COMPARATOR

Sham bevacizumab injection

Intervention Type DRUG

Sham intravitreal injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

bevacizumab

Intravitreal injection of 1.25 mg bevacizumab

Intervention Type DRUG

Sham bevacizumab injection

Sham intravitreal injection

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* CRVO with duration \< 6 months
* Visual acuity of 20/800 to 20/50

Exclusion Criteria

* CRVO with duration of \> 6 months
* previous treatment with anti-angiogenic drugs
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Anders Kvanta

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Anders Kvanta

Professor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anders Kvanta, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

St Eriks Eye Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

St Eriks Eye Hospital

Stockholm, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ACRVO

Identifier Type: -

Identifier Source: org_study_id